Publication at First Faculty of Medicine |
2015
Abstract
Pathogenesis of depression is still unknown, but recently growing evidence of the failure of regulation of the immune system in patients with depression. Depression in patients with rheumatoid arthritis occurs more frequently than in the general population.
Anti-inflammatory therapy with tocilizumab, a humanized monoclonal antibody against the receptor for interleukin 6, positively affects not only the activity of rheumatoid arthritis, as well as psychological symptoms, including depression in patients with rheumatoid arthritis.